Ocular Therapeutix™ Announces Appointment of New Board Member
Dr. Adrienne Graves to join Board of Directors BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE)…
Dr. Adrienne Graves to join Board of Directors BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE)…
Dr. Adrienne Graves to join Board of Directors BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE)…
RJ Tesi MD, CEO of INmune Bio, to Present Opening Keynote on Drug Development Strategies…
RJ Tesi MD, CEO of INmune Bio, to Present Opening Keynote on Drug Development Strategies…
Slynd® Slynd® is now reimbursed for 100% of Quebec women to whom it is indicated….
Slynd® Slynd® is now reimbursed for 100% of Quebec women to whom it is indicated….
Results Published in European Journal of Human Genetics Demonstrate Unprecedented Insights to Accelerate Potential Treatment…
Results Published in European Journal of Human Genetics Demonstrate Unprecedented Insights to Accelerate Potential Treatment…
New RIFF Wild Raspberry Lemonade and RIFF Blue Raspberry Ice Sparkling Drinks Infused with 10mg…
New RIFF Wild Raspberry Lemonade and RIFF Blue Raspberry Ice Sparkling Drinks Infused with 10mg…
WARMINSTER, Pa., July 12, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or…
WARMINSTER, Pa., July 12, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or…
Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and…
Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and…
Sudocetaxel zendusortide Phase 1 Trial to resume following FDA agreement to amended protocol Q2 2023…
Sudocetaxel zendusortide Phase 1 Trial to resume following FDA agreement to amended protocol Q2 2023…
Accomplished Industry Veteran Brings Deep Strategic and Operational Expertise CAMBRIDGE, Mass., July 12, 2023 (GLOBE…
Accomplished Industry Veteran Brings Deep Strategic and Operational Expertise CAMBRIDGE, Mass., July 12, 2023 (GLOBE…
SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics SparingVision remains focused on in vivo…
SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics SparingVision remains focused on in vivo…